Pfizer pays $15.4bn in cash, $1.75bn in debt for Hospira
Pfizer Inc. bought generics firm Hospira Inc. for $15.4bn in cash--$90 per share (a 39% premium)--plus $1.75bn in debt, and will finance the deal through a combination of cash (two-thirds) and debt (one-third).
- Drug Delivery
- Generic Drugs
- Diagnostic Imaging Equipment & Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.